MedPath

Sunitinib

Generic Name
Sunitinib
Brand Names
Sutent, Sunitinib Accord
Drug Type
Small Molecule
Chemical Formula
C22H27FN4O2
CAS Number
557795-19-4
Unique Ingredient Identifier
V99T50803M
Background

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

Indication

Sunitinib is indicated for the following conditions:

Associated Conditions
Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
Associated Therapies
-
Clinical Trials
Related News

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

Completed
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Drug: Sunitinib
First Posted Date
2019-09-03
Last Posted Date
2023-04-06
Lead Sponsor
Pfizer
Target Recruit Count
1769
Registration Number
NCT04076787
Locations
🇨🇦

University of Calgary, Calgary, Alberta, Canada

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Completed
Conditions
Carcinoma
Renal Cell
Interventions
Drug: Sunitinib
Drug: Axitinib
First Posted Date
2019-07-26
Last Posted Date
2023-04-06
Lead Sponsor
Pfizer
Target Recruit Count
684
Registration Number
NCT04033991
Locations
🇬🇧

Pfizer UK, London, United Kingdom

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Phase 2
Conditions
Metastasis
Colorectal Cancer
Interventions
Drug: TAS 102
Drug: Sunitinib Malate
First Posted Date
2019-04-10
Last Posted Date
2020-11-13
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
60
Registration Number
NCT03909724
Locations
🇳🇱

Radboud UMC, Nijmegen, Netherlands

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Phase 1
Terminated
Conditions
Renal Cell Carcinoma Metastatic
Interventions
Drug: Abemaciclib
Drug: Sunitinib
First Posted Date
2019-04-05
Last Posted Date
2024-06-25
Lead Sponsor
Brown University
Target Recruit Count
3
Registration Number
NCT03905889
Locations
🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

Losartan + Sunitinib in Treatment of Osteosarcoma

Phase 1
Recruiting
Conditions
Osteosarcoma
Interventions
Drug: Losartan
Drug: Sunitinib
First Posted Date
2019-04-03
Last Posted Date
2024-12-20
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
41
Registration Number
NCT03900793
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

🇺🇸

Children's Hospital of Atlanta, Atlanta, Georgia, United States

Pan Tumor Rollover Study

First Posted Date
2019-04-02
Last Posted Date
2025-01-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1500
Registration Number
NCT03899155
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

🇨🇦

Local Institution - 0040, Montreal, Quebec, Canada

🇨🇦

Local Institution - 0308, Montreal, Quebec, Canada

and more 304 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Not Applicable
Conditions
Gastrointestinal Stromal Tumors
Surgery
Interventions
Procedure: surgery
Drug: Imatinib escalation
Drug: Imatinib 400 MG
Drug: Sunitinib
First Posted Date
2019-03-05
Last Posted Date
2019-03-05
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
92
Registration Number
NCT03862768

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

First Posted Date
2018-12-07
Last Posted Date
2024-12-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03768063
Locations
🇺🇸

Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States

🇺🇸

HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States

and more 199 locations

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3
Terminated
Conditions
Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Interventions
Biological: bempegaldesleukin
Drug: sunitinib
Biological: nivolumab
Drug: cabozantinib
First Posted Date
2018-11-02
Last Posted Date
2023-04-11
Lead Sponsor
Nektar Therapeutics
Target Recruit Count
623
Registration Number
NCT03729245
Locations
🇺🇸

Alaska Urological, Anchorage, Alaska, United States

🇺🇸

CARTI Cancer Center, Little Rock, Arkansas, United States

🇦🇷

Centro de Investigación Pergamino S.A, Buenos Aires, Argentina

and more 92 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy